Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.72 |
| ▸ | S1PR5 | Q9H228 | 15/20 | 0.72 |
| ▸ | S1PR4 | O95977 | 13/20 | 0.72 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27712601 | 0.92 | S1PR1 (0.63) | S1PR1S1PR5S1PR4S1PR3HRH3 | |
| SCHEMBL1372761 | 0.84 | S1PR5 (1.00) | S1PR1S1PR5S1PR4S1PR3PDGFRA | |
| SCHEMBL6182824 | 0.82 | S1PR5 (1.00) | S1PR1S1PR5S1PR4S1PR3PDGFRA | |
| SCHEMBL5794112 | 0.81 | S1PR1 (0.52) | S1PR1S1PR5S1PR4S1PR3HRH3 | |
| SCHEMBL5794118 | 0.81 | S1PR5 (0.52) | S1PR1S1PR5S1PR4S1PR3HRH3 | |
| SCHEMBL13938026 | 0.80 | S1PR1 (0.78) | S1PR1S1PR5S1PR4S1PR3PDGFRA | |
| SCHEMBL14302589 | 0.79 | S1PR5 (0.78) | S1PR1S1PR5S1PR4S1PR3PDGFRA | |
| SCHEMBL4286843 | 0.79 | S1PR1 (0.61) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL4287128 | 0.79 | S1PR1 (0.58) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL4949657 | 0.78 | S1PR1 (0.67) | S1PR1S1PR5S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | claimed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | S1PR1 2/4885S1PR5 3/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.